BACE1 and Alzheimer disease: Their identification and validation would also allow the estimation of potential liabilities of BACE inhibitors in AD clinical trials and the use of BACE1 substrate cleavage products, in addition to Aβ, as possible companion diagnostics to monitor BACE1 inhibition in animals and patients.